MHRA-NICE aligned pathway gains early traction across 49 therapeutic areas
The MHRA-NICE aligned pathway is moving from concept to routine practice, with 90 topics scheduled since October 2025 across 49 therapeutic areas. The figure signals broad interest from the life sciences sector, spanning both multinational manufacturers and smaller companies, and it offers an early measure of how quickly regulatory and health technology assessment work can be brought into closer alignment in the UK.
A first medicine is expected to complete the aligned pathway later this year. Until that milestone arrives, the most meaningful data remain operational rather than clinical: the volume of topics queued, the range of therapeutic areas represented, and the growing use of a process designed to reduce delay between marketing authorisation and health technology assessment.
The model matters because timing shapes patient access. In a system where licensing and reimbursement decisions have traditionally moved on parallel tracks, even modest gains in coordination can shorten the interval between approval and routine availability. For medicines aimed at serious disease, those weeks can alter the pace at which treatment reaches clinics, specialist centres, and, ultimately, patients waiting for options that have already cleared regulatory review.
Operational alignment is already changing the pace of guidance
Closer working between the Medicines and Healthcare products Regulatory Agency and NICE is already affecting medicines that sit outside the formal aligned pathway. A recent example is aficamten, a daily treatment for obstructive hypertrophic cardiomyopathy, where final NICE guidance was published alongside the MHRA marketing authorisation decision and two weeks faster than NICE’s standard process. Around 6,600 people in England with this condition are expected to gain access sooner as a result.
For a disease such as obstructive hypertrophic cardiomyopathy, where left ventricular outflow obstruction drives symptoms and limits exertion, a faster route to guidance can have direct bedside implications. Earlier reimbursement clarity means cardiology teams can move sooner from diagnosis and risk stratification to treatment planning, without waiting through a prolonged gap between regulatory approval and health system endorsement.
The process is underpinned by data sharing agreements between the two organisations, with commercially sensitive information handled under strict confidentiality protocols. Public accountability remains part of the design. NICE continues to hold committee meetings in public, and draft guidance issued before marketing authorisation is clearly framed as provisional, contingent on MHRA approval of the licence.
Integrated scientific advice is designed to shape development earlier
The other major strand of the update is integrated scientific advice. Since launch in April 2026, three integrated scientific advice projects have begun. The service is intended to help companies define regulatory and health technology assessment evidence requirements early enough to influence development plans before pivotal studies are locked in.
The structure is deliberately streamlined: one enquiry form, one advice meeting, one report, and one payment. That simpler workflow is paired with lower fees than the previous joint scientific advice model, with costs around 25% lower overall and 40% lower for small and medium-sized enterprises. For smaller developers, the reduction may matter as much as the advice itself, because evidence-generation budgets are often the limiting factor long before a product reaches review.
A single client described the process as “seamless.” More feedback will accumulate as projects mature, but the early signal is consistent with the service’s basic aim: to reduce friction between development strategy, regulatory expectations, and the evidence NICE will later need to appraise comparative benefit, uncertainty, and value for money.
Earlier advice can reduce downstream evidence mismatch
Early scientific advice is most useful when it arrives before final pivotal study plans are fixed. At that stage, sponsors still have room to adjust endpoints, comparators, patient populations, and follow-up duration so the eventual dossier answers both licensing and appraisal questions. In practical terms, that can prevent a familiar failure mode: a technically successful trial that does not generate the exact evidence framework needed for health system adoption.
The aligned pathway and the advice service are open to all companies. Registration for the aligned pathway should occur on UK PharmaScan at least three years before expected marketing authorisation, with no separate application and no additional fee. Companies considering suitability can contact NICE directly for discussion. For integrated scientific advice, the request process sits through GOV.UK, and companies are encouraged to seek input two to five years before marketing authorisation.
That timing is not merely administrative. It is the point at which protocol design can still absorb regulatory and reimbursement requirements without forcing a costly redesign later. A development programme that enters late advice with fixed assumptions has far less room to adapt than one that uses the process before pivotal study plans harden.
The next test is whether early gains scale into routine practice
The next clear checkpoint is the first medicine to complete the aligned pathway later this year. Until then, the update mainly demonstrates that the machinery is working: topics are being scheduled, advice projects are being started, and at least one medicine has already benefited from faster coordinated handling even outside the formal pathway.
What remains unresolved is scale. The update does not provide comparative failure rates, review-cycle distributions, or evidence that the pathway consistently shortens access timelines across therapeutic areas. It also does not show how often integrated scientific advice changes study design, or whether lower fees translate into wider uptake among smaller developers over time. Those are the questions that will determine whether the early operational gains become standard practice or remain isolated examples of smoother collaboration.